Rezolute Q3 FY2026 net loss $16.2M, cash $120.3M; Phase 3 sunRIZE shows >50% hypoglycemia reduction

Rezolute, Inc.

2026-Q3 EPS reported -$0.55

Net loss $16.2M vs $18.9M YoY; R&D expense $11.4M, down from $15.3M.
Cash and investments $120.3M at Mar 31, 2026, down from $167.9M at Jun 30, 2025.
Phase 3 sunRIZE: ersodetug reduced time in hypoglycemia by >50% (FAS) and 60-80% (PPS) vs placebo.
FDA Type B meeting in March 2026 acknowledged congenital HI challenges; Rezolute to submit comprehensive datasets.
Tumor HI Phase 3 upLIFT trial enrolling; topline results expected H2 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Rezolute, Inc. reported for the three months ended March 31, 2026 results: net income $16.2 million.

Period: for the three months ended March 31, 2026
Net income: $16.2 million
Result: reported results

Exact text from the filing

Net loss was $16.2 million for the third quarter of fiscal 2026 compared with a net loss of $18.9 million for the same period a year ago.

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Rezolute, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-059392

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.